Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors-Reference-Cited by-同舟云学术

Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Published:2012-10-15 Issue:22 Volume:55 Page:9416-9433
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Estrada Anthony A.,Liu Xingrong,Baker-Glenn Charles,Beresford Alan,Burdick Daniel J.,Chambers Mark,Chan Bryan K.,Chen Huifen,Ding Xiao,DiPasquale Antonio G.¹,Dominguez Sara L.,Dotson Jennafer,Drummond Jason,Flagella Michael,Flynn Sean,Fuji Reina,Gill Andrew,Gunzner-Toste Janet,Harris Seth F.,Heffron Timothy P.,Kleinheinz Tracy,Lee Donna W.,Le Pichon Claire E.,Lyssikatos Joseph P.,Medhurst Andrew D.,Moffat John G.,Mukund Susmith,Nash Kevin,Scearce-Levie Kimberly,Sheng Zejuan,Shore Daniel G.,Tran Thuy,Trivedi Naimisha,Wang Shumei,Zhang Shuo,Zhang Xiaolin,Zhao Guiling,Zhu Haitao,Sweeney Zachary K.

Affiliation:

1. X-ray Crystallographic Facility, University of California—Berkeley, 32 Lewis Hall, Berkeley, California 94720, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm301020q

Reference68 articles.

1. Parkinson's disease

2. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

3. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease

4. LRRK2 in Parkinson's disease: protein domains and functional insights

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease;International Encyclopedia of Public Health;2025

2. Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors;Journal of Medicinal Chemistry;2024-09-04

3. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson’s Disease;The Journal of Physical Chemistry B;2024-06-01

4. Concurrent Optimizations of Efficacy and Blood–Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson’s Disease Therapeutics;Journal of Medicinal Chemistry;2024-04-29

5. Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases;ACS Chemical Neuroscience;2024-04-22